Affini-T Therapeutics to Present Preclinical Data from its Lead Programs Targeting KRAS G12V at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

BOSTON, Mass., and SEATTLE, Wash. – November 7, 2022 – Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that data from its oncogenic driver programs targeting KRAS G12V will be presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting. “Patients are the central […]

Affini-T Therapeutics Named to the 2022 Endpoints 11

BOSTON, Mass., and SEATTLE, Wash. – September 22, 2022 – Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, has been selected by Endpoints News Editor John Carroll as one of the most promising startups in biotech for his annual report on the Endpoints 11. “We are honored […]

Affini-T Therapeutics Appoints Jill DeSimone to its Board of Directors

BOSTON, Mass., and SEATTLE, Wash. – July 12, 2022 – Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced the appointment of Jill DeSimone to its board of directors. Ms. DeSimone brings more than 40 years of global business expertise in life sciences to Affini-T’s board. […]

Affini-T Therapeutics & Metagenomi Announce Next-Generation Gene Editing Partnership to Advance Cell Therapies for Solid Tumor Patients

BOSTON, Mass., and SEATTLE, Wash., and EMERYVILLE, Calif., June 15th, 2022 – Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, and Metagenomi, Inc., a genetic medicines company with a versatile portfolio of next-generation, wholly-owned gene editing tools, today announced a partnership to enable Affini-T’s next generation ex […]

Affini-T Therapeutics to Present at Upcoming Investor and Industry Conferences

BOSTON & SEATTLE–(BUSINESS WIRE)–Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced three presentations at upcoming investor and industry conferences. Jak Knowles, M.D., Co-founder, President and Chief Executive Officer of Affini-T Therapeutics, will present at each discussing the company’s T cell receptor (TCR) discovery platform, lead […]

Clinical Strategy for Enhancing Affini-T Therapeutics’ Merkel Polyoma Virus TCR Therapy to be Presented at ASCO 2022

BOSTON, Mass., and SEATTLE, Wash. – June 2, 2022 – Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that the clinical strategy for enhancing the efficacy of its Merkel cell polyomavirus (MCPyV)-specific T cell receptor (TCR) program for the treatment of PD-1 refractory Merkel cell carcinoma (MCC), from […]